New results come from an interim analysis of a phase 3 randomized trial comparing maintenance therapy with ribociclib plus endocrine therapy with an aromatase inhibitor to endocrine therapy alone.

Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers expressing PD-L1.

After 6 months, patients who received telephone coaching and health education lost 9.7 pounds.

Results of a new study were particularly notable for Black patients, for whom there was a consistent increase in receiving therapy and a decrease in mortality from stomach, colorectal, and pancreatic cancer.

The immune checkpoint inhibitor nivolumab affords unprecedented improvement in “harmonizing” treatment for adult and pediatric Hodgkin lymphoma patients.

Survival from pediatric acute lymphoblastic leukemia (ALL) in a Mexican hospital improved significantly through a close cross-border collaboration with a nearby U.S. center that provided training and improved access.

Almost all patients who skipped chemotherapy avoided invasive disease/death at 3 years.

The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.